### **Barriers to Access**

- Streamline prior authorization requests and establish mandatory exceptions to avoid patient harm and minimize prior authorizations for routinely approved medications. Also:
  - ☐ Reform the appeals process.
  - ☐ Allow electronic submissions.
- **Reform step therapy** through guardrails to protect physician-patient decision-making in federal and state government-regulated health plans.
- **Eliminate copay accumulator policies** in federal and state government-regulated health plans.
- Prohibit non-medical switching to ensure patients can be treated with the medications providers determine to be most effective and to protect patients from mid-year formulary changes.
- Support provider financial solvency and policies to maintain independent medical practices.

### **Access to Treatments**

- Modify pharmacy benefit manager (PBM) operations to implement greater transparency and oversight, ensure rebate savings are passed through to patients, and "delink" PBM income from the drug prices they negotiate.
- Reduce the cost of treating the patient without restricting the ability of rheumatologists and their healthcare team to safely treat patients by:
  - ☐ Redesigning Medicare Part D (out-of-pocket costs).
- ☐ Adequately reimbursing for biosimilar products.
- Establish guardrails around white bagging policies.
- Oppose any mandatory Part B demonstration projects that threaten access to in-office treatments.

#### **Telehealth**

- **Protect continued access** to telehealth appointments to supplement patient care by:
  - Preserving reimbursement parity for virtual appointments with providers.
  - ☐ Resolving inter-state licensing issues arising from cross-border telemedicine use.
  - Appropriately reimbursing audio-only telehealth services to preserve access.

### **Medicare Reimbursement**

- Secure appropriate reimbursement for services to maintain Medicare patient access to care through the physician fee schedule (PFS) by:
  - □ Repealing sequestration cuts, repealing the balanced budget requirement, and updating the PFS annually for inflation per the Medicare Economic Index [MEI].
- Protect the 2021 evaluation and management (E/M) payment updates and recognize the value of these services through more frequent valuations.

### Workforce

- Expand the rheumatology workforce by permanently repealing the cap on Medicare funding training positions and adequately funding **Graduate Medical Education (GME)** positions.
- **Ease the burden of** *medical education loans* by supporting loan repayment and forgiveness.
- Reduce barriers to joining the American medical workforce for international medical graduates and foreign nationals appropriately situated to practice in the U.S.

## **Research Funding**

- Increase biomedical research funding at the National Institutes of Health (NIH) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and establish a dedicated arthritis study section.
- Support and promote the growth of the Arthritis Program in the Division of Population Health of the Centers for Disease Control and Prevention (CDC).
- Maintain and grow the dedicated arthritis research funding in the Congressionally Directed Medical Research Program (CDMRP) at the Department of Defense (DOD).

# **Medicare Advantage**

Increase transparency requirements and patient education around benefits, cost, coverage, and providers for Medicare Advantage Organizations.

Visit **RheumPAC.org** for more ways to support rheumatology advocacy